Intervención para la racionalización del uso de losartán

Poulter, 2015, Hypertension, Lancet., 386, 801, 10.1016/S0140-6736(14)61468-9 Machado-Alba, 2013, Effectiveness of lipid-lowering therapy among a sample of patients in Colombia, Rev Panam Salud Publica., 33, 383 Munger, 2011, Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions, P T., 36, 22 Gottlieb, 1993, Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure, Circulation., 88, 1602, 10.1161/01.CIR.88.4.1602 Konstam, 2009, Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial, Lancet., 374, 1840, 10.1016/S0140-6736(09)61913-9 Machado-Alba, 2016, Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases, Biomédica., 36, 59 Taddei, 2011, The correct administration of antihypertensive drugs according to the principles of clinical pharmacology, Am J Cardiovasc Drugs., 11, 13, 10.2165/11586670-000000000-00000 Fernández Urrusuno, 2012, Quality prescribing of long-acting beta-agonists. Results of an intervention in Primary Care, Rev Calid Asist., 27, 11, 10.1016/j.cali.2011.06.004 Machado-Alba, 2015, Quality of conventional release verapamil prescription in patients with arterial hypertension, Rev Calid Asist., 30, 72, 10.1016/j.cali.2015.01.009 James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA., 311, 507, 10.1001/jama.2013.284427 Evans, 2012, Pharmacoepidemiology, Br J Clin Pharmacol, 73, 973, 10.1111/j.1365-2125.2012.04248.x Machado-Alba, 2015, Results of the inclusion of new medications in the obligatory health system plan in Colombia, 2012-2013, Value Health Reg Issues., 8C, 28, 10.1016/j.vhri.2015.02.002